Polymorphs Of Ibrutinib

CLAIMS: We Claim: 1. Crystalline form D1 of Ibrutinib characterized by an X-ray Powder Diffraction Pattern (PXRD) having peaks at about 10.11, 11.45, 18.47 and 20.89 ± 0.20 degrees 2Ɵ. 2. Crystalline form D1 of Ibrutinib of claim 1, further characterized by PXRD pattern having additional peaks located at about 5.04, 10.79, 23.10 and 26.60 ± 0.20 degrees 2Ɵ. 3. Crystalline form D1 of Ibrutinib characterized by an X-ray Powder Diffraction Pattern (PXRD) as shown figure 18. 4. A process for preparing crystalline Form D1 of Ibrutinib, comprising the steps of: a. obtaining a solution of ibrutinib in an alcohol; b. combining the solution of step a) with an anti-solvent; and c. isolating crystalline form D1 of Ibrutinib. 5. The process of claim 4 wherein, the alcohol is selected from methanol, ethanol, propanol, isopropanol, butanol, iso-butanol and pentanol. 6. The process of claim 4 wherein, the anti-solvent is water.